Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Phase 1

Completed

Conditions: Lung Cancer
Colorectal Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: carboplatin
Drug: cediranib maleate
Drug: paclitaxel

First Posted Date: 2005-04-06

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 50

Registration Number: NCT00107250

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine
Drug: oxaliplatin

First Posted Date: 2005-03-04

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 60

Registration Number: NCT00104689

Locations: 🇫🇷
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France
🇫🇷
Centre Regional Francois Baclesse, Caen, France
🇫🇷
Institut Jean Godinot, Reims, France

and more 6 locations

Title XELOX FOR SALIVARY GLAND CANCERS

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2005-01-10

Last Posted Date: 2017-02-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00101075

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2005-01-07

Last Posted Date: 2015-12-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 50

Registration Number: NCT00100815

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Capecitabine For Nasopharyngeal Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2004-11-09

Last Posted Date: 2018-03-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT00095901

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer

Phase 2

Withdrawn

Conditions: Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity

First Posted Date: 2004-11-08

Last Posted Date: 2013-11-08

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT00095641

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

Phase 2

Completed

Conditions: Anal Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin
Radiation: Radiation Therapy (XRT)

First Posted Date: 2004-10-08

Last Posted Date: 2023-04-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00093379

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: capecitabine
Drug: vinorelbine tartrate

First Posted Date: 2004-10-08

Last Posted Date: 2017-03-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 47

Registration Number: NCT00093808

Locations: 🇺🇸
Graham Hospital, Canton, Illinois, United States
🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States

and more 140 locations